|
|
|
|
|
|
|
|
|
|
|
|
|
24.10.25 - 22:33
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
03.10.25 - 22:33
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the company and 34,564 restricted stock units of the company's common stock to one newly hired non-executive officer employee of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 30, 2025, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
30.09.25 - 22:09
|
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions....
|
|
|
|
|
|
|
19.09.25 - 22:33
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
29.08.25 - 22:33
|
Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences....
|
|
|
21.08.25 - 23:03
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of the company's common stock to 33 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
